TP53 and lung adenocarcinoma: Recently, Skoulidis et al. demonstrated that co-occurring genetic alterations in STK11, TP53, and CDKN2A/B define three major subgroups of KRASMUT lung adenocarcinoma with distinct biology and therapeutic vulnerabilities [29].